Rapid review finds molnupiravir, nirmatrelvir–ritonavir, and simnotrelvir–ritonavir increased recovery or reduced time to recovery with varying adverse event profiles, and molnupiravir could have long-term benefits for 3 to 6 months.
While shorter time to blood culture positivity was linked with infective endocarditis, it was not associated with mortality or sepsis in Streptococcus agalactiae bacteremia.